Your browser doesn't support javascript.
loading
Linagliptin and telmisartan induced effects on renal and urinary exosomal miRNA expression in rats with 5/6 nephrectomy.
Delic, Denis; Wiech, Franziska; Urquhart, Richard; Gabrielyan, Ogsen; Rieber, Kathrin; Rolser, Marcel; Tsuprykov, Oleg; Hasan, Ahmed A; Krämer, Bernhard K; Baum, Patrick; Köhler, Andreas; Gantner, Florian; Mark, Michael; Hocher, Berthold; Klein, Thomas.
Afiliación
  • Delic D; Boehringer Ingelheim Pharma GmbH & Co. KG, Translational Medicine & Clinical Pharmacology, Biberach, Germany. denis.delic@boehringer-ingelheim.com.
  • Wiech F; Boehringer Ingelheim Pharma GmbH & Co. KG, Translational Medicine & Clinical Pharmacology, Biberach, Germany.
  • Urquhart R; Boehringer Ingelheim Pharma GmbH & Co. KG, Translational Medicine & Clinical Pharmacology, Biberach, Germany.
  • Gabrielyan O; Boehringer Ingelheim Pharma GmbH & Co. KG, Translational Medicine & Clinical Pharmacology, Biberach, Germany.
  • Rieber K; Boehringer Ingelheim Pharma GmbH & Co. KG, Translational Medicine & Clinical Pharmacology, Biberach, Germany.
  • Rolser M; Boehringer Ingelheim Pharma GmbH & Co. KG, Translational Medicine & Clinical Pharmacology, Biberach, Germany.
  • Tsuprykov O; Fifth Department of Medicine (Nephrology/Endocrinology/Rheumatology), University Medical Centre Mannheim, University of Heidelberg, Heidelberg, Germany.
  • Hasan AA; Fifth Department of Medicine (Nephrology/Endocrinology/Rheumatology), University Medical Centre Mannheim, University of Heidelberg, Heidelberg, Germany.
  • Krämer BK; Department of Biochemistry, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt.
  • Baum P; Fifth Department of Medicine (Nephrology/Endocrinology/Rheumatology), University Medical Centre Mannheim, University of Heidelberg, Heidelberg, Germany.
  • Köhler A; Boehringer Ingelheim Pharma GmbH & Co. KG, Translational Medicine & Clinical Pharmacology, Biberach, Germany.
  • Gantner F; Boehringer Ingelheim Pharma GmbH & Co. KG, Translational Medicine & Clinical Pharmacology, Biberach, Germany.
  • Mark M; Boehringer Ingelheim Pharma GmbH & Co. KG, Translational Medicine & Clinical Pharmacology, Biberach, Germany.
  • Hocher B; Boehringer Ingelheim Pharma GmbH & Co. KG, Cardiometabolic Diseases Research, Biberach, Germany.
  • Klein T; Fifth Department of Medicine (Nephrology/Endocrinology/Rheumatology), University Medical Centre Mannheim, University of Heidelberg, Heidelberg, Germany. berthold.hocher@medma.uni-heidelberg.de.
Sci Rep ; 10(1): 3373, 2020 02 25.
Article en En | MEDLINE | ID: mdl-32099009
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Regulación de la Expresión Génica / MicroARNs / Bloqueadores del Receptor Tipo 1 de Angiotensina II / Inhibidores de la Dipeptidil-Peptidasa IV / Exosomas / Linagliptina / Telmisartán / Riñón Límite: Animals Idioma: En Revista: Sci Rep Año: 2020 Tipo del documento: Article País de afiliación: Alemania
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Regulación de la Expresión Génica / MicroARNs / Bloqueadores del Receptor Tipo 1 de Angiotensina II / Inhibidores de la Dipeptidil-Peptidasa IV / Exosomas / Linagliptina / Telmisartán / Riñón Límite: Animals Idioma: En Revista: Sci Rep Año: 2020 Tipo del documento: Article País de afiliación: Alemania